Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.66 |
| ▸ | BRAF | P15056 | 12/20 | 0.62 |
| ▸ | EGFR | P00533 | 10/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | CLK1 | P49759 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4910277 | 0.99 | KIT (0.67) | KITBRAFEGFRHTTCLK1 | |
| SCHEMBL4901580 | 0.96 | KIT (0.64) | KITBRAFEGFRHTTCLK1 | |
| SCHEMBL4906673 | 0.91 | KIT (0.79) | KITBRAFEGFRABL1 | |
| SCHEMBL4910210 | 0.90 | KIT (0.64) | KITBRAFEGFRHTTCLK1 | |
| SCHEMBL4903423 | 0.87 | KIT (0.76) | KITBRAFEGFRABL1 | |
| SCHEMBL4908467 | 0.87 | KIT (0.61) | KITBRAFEGFRHTTABL1 | |
| SCHEMBL23048203 | 0.83 | KIT (0.76) | KITBRAFEGFRABL1 | |
| SCHEMBL12871531 | 0.82 | KIT (0.84) | KITBRAFEGFRABL1 | |
| SCHEMBL4903601 | 0.81 | HTT (0.56) | KITBRAFEGFRHTTCLK1 | |
| SCHEMBL13660025 | 0.81 | KIT (0.67) | KITBRAFEGFRHTTCLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101696188-A | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG | 2010-04-21 | — | — | CN | disclosed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
| CN-101039914-A | Trifluoromethyl substituted benzamide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2007-09-19 | — | — | CN | disclosed |
| EP-1778640-A1 | TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006015859-A1 | TRIFLUOROMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-02-16 | — | — | WO | disclosed |
| US-20060035897-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096883-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | MAP3K1, MAP3K20, MAP3K2 | KIT 262/4885BRAF 6/4885EGFR 252/4885 |
| US-20060035897-A1 | Trifluoromethyl substituted benzamides as kinase inhibitors | ABL1, ERBB2, EPHB2 | KIT 276/4885BRAF 6/4885EGFR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.